Objective: High-risk human papilloma virus (HPV) testing should be performed on all patients with newly diagnosed oropharyngeal HPV-associated squamous cell carcinoma (OPHPVSCC), and p16 immunostaining can be used as a surrogate marker. Although in surgical pathology specimens p16 staining in > 70% of the tumor cells is considered a positive result, the interpretation in fine-needle aspiration (FNA) specimens has remained controversial. Study Design: FNA of neck lymph nodes and corresponding surgical specimens from 42 patients with OPHPVSCC were reviewed. Results: In FNA specimens, 38 cases (90.5%) had viable tumor cells, 32 (76.2%) had keratin debris, and 36 (85.7%) had degenerated keratinized tumor cells. Twenty-seven of 27 (100%) had positive p16 staining in > 70% of viable tumor cells, while the degenerated tumor cells were negative. Twenty of 24 (83.3%) primary OPHPVSCC exhibited focal degenerated keratinized tumor cells and/or keratin debris. Conclusions: This study showed that the majority of the OPHPVSCC metastases in lymph nodes had degenerated keratinized tumor cells and keratin debris. Many primary OPHPVSCC also demonstrated focal keratinization and/or degeneration. The degenerated tumor cells showed no immunoreactivity to p16. The same 70% cutoff used in histologic specimens should be applied in cytologic specimens, but only the viable tumor cells should be counted.

1.
El-Naggar A, Chan J, Grandis J, Takata T, Slootweg P: WHO Classification of Head and Neck Tumours. Lyon, IARC, 2017.
2.
Jannapureddy S, Cohen C, Lau S, Beitler JJ, Siddiqui MT: Assessing for primary oropharyngeal or nasopharyngeal squamous cell carcinoma from fine needle aspiration of cervical lymph node metastases. Diagn Cytopathol 2010; 38: 795–800.
3.
Bernadt CT, Collins BT: Fine-needle aspiration biopsy of HPV-related squamous cell carcinoma of the head and neck: current ancillary testing methods for determining HPV status. Diagn Cytopathol 2017; 45: 221–229.
4.
Lewis JS Jr, Beadle B, Bishop JA, Chernock RD, Colasacco C, Lacchetti C, Moncur JT, Rocco JW, Schwartz MR, Seethala RR, Thomas NE, Westra WH, Faquin WC: Human papillomavirus testing in head and neck carcinomas: guideline from the College of American Pathologists. Arch Pathol Lab Med 2018; 142: 559–597.
5.
Stevens TM, Bishop JA: HPV-related carcinomas of the head and neck: morphologic features, variants, and practical considerations for the surgical pathologist. Virchows Arch 2017; 471: 295–307.
6.
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24–35.
7.
Bishop JA, Lewis JS Jr, Rocco JW, Faquin WC: HPV-related squamous cell carcinoma of the head and neck: an update on testing in routine pathology practice. Semin Diagn Pathol 2015; 32: 344–351.
8.
Jalaly JB, Lewis JS Jr, Collins BT, Wu X, Ma XJ, Luo Y, Bernadt CT: Correlation of p16 immunohistochemistry in FNA biopsies with corresponding tissue specimens in HPV-related squamous cell carcinomas of the oropharynx. Cancer Cytopathol 2015; 123: 723–731.
9.
Maxwell JH, Grandis JR, Ferris RL: HPV-associated head and neck cancer: unique features of epidemiology and clinical management. Annu Rev Med 2016; 67: 91–101.
10.
Begum S, Gillison ML, Nicol TL, Westra WH: Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13: 1186–1191.
11.
Holmes BJ, Maleki Z, Westra WH: The fidelity of p16 staining as a surrogate marker of human papillomavirus status in fine-needle aspirates and core biopsies of neck node metastases: implications for HPV testing protocols. Acta Cytol 2015; 59: 97–103.
12.
Mills AM, Beck AH, Pourmand N, Le QT, Kong CS: Evaluation of ProExC as a prognostic marker in oropharyngeal squamous cell carcinomas. Am J Surg Pathol 2012; 36: 1158–1164.
13.
Xu B, Ghossein R, Lane J, Lin O, Katabi N: The utility of p16 immunostaining in fine needle aspiration in p16-positive head and neck squamous cell carcinoma. Hum Pathol 2016; 54: 193–200.
14.
Chernock RD: Morphologic features of conventional squamous cell carcinoma of the oropharynx: “keratinizing” and “nonkeratinizing” histologic types as the basis for a consistent classification system. Head Neck Pathol 2012; 6(suppl 1):S41–S47.
15.
Chernock RD, El-Mofty SK, Thorstad WL, Parvin CA, Lewis JS Jr: HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head Neck Pathol 2009; 3: 186–194.
16.
Lewis JS Jr, Thorstad WL, Chernock RD, Haughey BH, Yip JH, Zhang Q, El-Mofty SK: p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 2010; 34: 1088–1096.
17.
El-Mofty SK, Zhang MQ, Davila RM: Histologic identification of human papillomavirus (HPV)-related squamous cell carcinoma in cervical lymph nodes: a reliable predictor of the site of an occult head and neck primary carcinoma. Head Neck Pathol 2008; 2: 163–168.
18.
El-Mofty SK: Human papillomavirus-related head and neck squamous cell carcinoma variants. Semin Diagn Pathol 2015; 32: 23–31.
19.
Jarboe EA, Hunt JP, Layfield LJ: Cytomorphologic diagnosis and HPV testing of metastatic and primary oropharyngeal squamous cell carcinomas: a review and summary of the literature. Diagn Cytopathol 2012; 40: 491–497.
20.
Mahajan A: Practical issues in the application of p16 immunohistochemistry in diagnostic pathology. Hum Pathol 2016; 51: 64–74.
21.
Robinson M, Schache A, Sloan P, Thavaraj S: HPV specific testing: a requirement for oropharyngeal squamous cell carcinoma patients. Head Neck Pathol 2012; 6(suppl 1):S83–S90.
22.
Bishop JA, Maleki Z, Valsamakis A, Ogawa T, Chang X, Pai SI, Westra WH: Application of the hybrid capture 2 assay to squamous cell carcinomas of the head and neck: a convenient liquid-phase approach for the reliable determination of human papillomavirus status. Cancer Cytopathol 2012; 120: 18–25.
23.
Guo M, Khanna A, Dhillon J, Patel SJ, Feng J, Williams MD, Bell DM, Gong Y, Katz RL, Sturgis EM, Staerkel GA: Cervista HPV assays for fine-needle aspiration specimens are a valid option for human papillomavirus testing in patients with oropharyngeal carcinoma. Cancer Cytopathol 2014; 122: 96–103.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.